Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

Study: Legalizing cannabis reduces opioid prescriptions

States that have legalized adult-use marijuana have a significant reduction pharmacy-based codeine prescriptions a new study shows. The study was published January 19 in the Journal of Health Economics.

Using data from the federal Drug Enforcement Administration which tracks controlled substances across the U.S., the study looked at 11 states that had legalized adult-use cannabis between 2010 and 2019. Researchers found that there was a 26 percent reduction in “pharmacy-based distribution of codeine” and after four years many states experienced as much as a 37 percent reduction.

The study comes out as cannabis advocates urge the Texas Legislature to expand the state’s extremely limited medical marijuana program to include patients with chronic pain. Those in favor of the expansion argue that it will help qualifying Texans find relief without accessing addictive and potentially dangerous opioids.

Codeine is an opioid, and prescription opioids contribute to more than 10,000 overdose U.S. deaths annually. But codeine is just one such opioid prescription, and the study found that marijuana legalization had “minimal impact on distribution of other opioids such as oxycodone, hydrocodone and morphine in any setting.” Plus, marijuana legalization didn’t have an impact on hospital-distribution of codeine.

Researchers speculated that the pharmacy-based reduction is because codeine is a weaker opioid with a high potential for addiction. Since cannabis, like codeine, can help reduce chronic pain, its legalization can shift consumers away from opioid misuse and towards cannabis.

“A reduction in the misuse of opioids will save lives,” said Shyam Raman, a doctoral candidate at Cornell University and lead author of the study. “Our research indicated that recreational cannabis laws substantially reduce distribution of codeine to pharmacies, an overlooked potential benefit to legalizing recreational cannabis use.”

The study further confirms what other studies have found, that given the option, patients will often substitute marijuana for opioid painkillers. In 2019, the Journal of Pain came to this conclusion using online surveys submitted by adult cannabis users. When survey respondents were asked why they’d made the change, they sited fewer adverse side effects and more success managing symptoms.

Harm Reduction Journal published a similar study in 2019 that was based on a survey of 2,000 Canadian adult-use marijuana users.

Study: Legalizing cannabis reduces opioid prescriptions

About Cannin: Your Cannabis Stocks Resource

78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.

Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. In fact, we aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021.

Use Cannin as your resource for:

Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Are you looking to buy stock in hemp companies or marijuana companies for 2021? If so, are you interested in new penny hemp stock companies? Or, looking for the best Canadian cannabis stocks to invest in? Maybe, you’re looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.

Are you interested in cannabis stocks like CuraleafTrulieveAurora CannabisCharlotte’s WebCanopy Growth, or Hemp Inc.?

Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +34% Gains in 2022
  • +56% Gains in 2021
  • +30% Gains in 2020
  • +49.8% Gains in 2019
  • Backtested since 2012

In fact, we’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one week risk-free trial to see it for yourself.

Profit from the best cannabis stocks – we’ll show you how at